Every 10-Q that HeartSciences Inc. Warrant (HSCSW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HSCSW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HSCSW filings page.
HeartSciences Inc. (HSCS) reported another loss-making quarter and a strained balance sheet while pursuing a transformative merger with Fortitude Mining HoldCo. For the quarter ended July 31, 2026, revenue was only $2,100 and the company recorded a net loss of $3.17 million, wider than the prior-year loss of $2.05 million. Cash and cash equivalents fell to just $29,906, and stockholders’ equity shifted to a deficit of $2.03 million, prompting Nasdaq to notify HSCS that it no longer meets the $2.5 million equity listing requirement. Management discloses “substantial doubt” about the company’s ability to continue as a going concern and is relying on additional capital raises, including an at-the-market program and a $1.0 million private placement to Fortitude’s parent, and on closing the proposed Merger, under which Fortitude holders are expected to own about 95% of the combined company.
HeartSciences Inc. reported another loss-making quarter for the period ended January 31, 2026, with a nine‑month net loss of $6.4 million and minimal revenue of $4,319. Operating expenses were driven by research and development and general and administrative costs, while interest expense added further pressure.
Cash and cash equivalents were $3.4 million against $7.6 million in total assets and $4.9 million in total liabilities, leaving stockholders’ equity at $2.7 million. The company discloses substantial doubt about its ability to continue as a going concern and is relying on external financing, including a $3.6 million Streeterville note and a Series D preferred stock offering that raised about $6.7 million.
HeartSciences, Inc. reported financing activity, corporate actions and development progress for its MyoVista wav ECG and cloud platform. The company completed a 100-for-1 reverse stock split and issued Units consisting of Series D Preferred Stock plus warrants, selling 1,317,689 Units for gross proceeds of approximately $4.6 million during the quarter and an additional 238,720 Units for approximately $0.8 million subsequent to period end, with up to $15.0 million available under the offering. Common shares outstanding increased to 2,281,054 as of July 31, 2025 from 1,119,107 on April 30, 2025. The company is preparing FDA submissions for the MyoVista wav ECG but does not yet have FDA clearances for AI-ECG algorithms. Inventory related to finished devices will be updated for limited field studies and may require additional write-downs if FDA clearance or market acceptance is not obtained. The company has loan obligations totaling $1.0 million from related-party lenders that accrue interest at 12% per annum (default 18%) and are secured by substantially all assets. HeartSciences currently notes a Nasdaq listing deficiency and is taking steps to regain compliance.